查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1576770

融合蛋白市场，按产品类型、应用、最终用户、治疗领域 - 全球预测 2025-2030

Fusion Proteins Market by Product Type (Chemically Synthesized Fusion Proteins, Recombinant Fusion Proteins), Application (Diagnostic Applications, Research Applications, Therapeutic Applications), End User, Therapeutic Area - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

按产品类型、应用、最终用户和治疗领域划分，2023 年融合蛋白市场价值为 270.2 亿美元，预计到 2024 年将达到 295.8 亿美元，复合年增长率为 10.49%，预计将达到 2024 年。为543.4亿。

从产品类型、应用、最终用户和治疗领域来看，融合蛋白是生物技术的革命性进步，是由两种不同的蛋白质序列基因融合形成的人工蛋白质，具有多方面的生物学功能，从而形成单一的多肽链。该技术增强了标靶递送和治疗功效，使其在肿瘤学、自体免疫疾病和酵素替代疗法等领域至关重要。其应用范围广泛，可用于药物开发、药物传输系统、诊断，甚至农业。最终用户主要是製药公司、生技公司、研究机构和医疗机构。由于对新型生技药品的需求不断增加、基因工程的进步以及生物技术领域投资的增加，按产品类型、应用、最终用户和治疗领域分類的融合蛋白市场预计将显着增长。主要成长动力包括慢性病的流行、对具有成本效益的生物製药的需求以及蛋白质工程的技术进步。在免疫疗法和个人化医疗的发展中，由于对标靶治疗的需求，商机正在迅速增加。然而，仍存在阻碍市场成长的挑战，例如高昂的研发成本、严格的监管条件和复杂的製造流程。道德问题和专利问题也是限制因素。为了取得成功，公司应该专注于 CRISPR、人工智慧主导的蛋白质设计等创新技术，以及提高融合蛋白的特异性和稳定性的先进分子技术。与学术和研究机构的联盟与合作也可以促进新发现和产品开发。市场是动态的，其特点是快速的技术进步和竞争力量，这要求企业保持灵活性和适应能力。合成生物学领域的创新和开拓新的治疗领域来解决未满足的需求可以提供利润丰厚的成长途径。有抱负的公司应该采取利用这些创新的策略，并简化生产和监管流程，以实现最佳的市场渗透。

主要市场统计
基准年[2023] 270.2亿美元
预测年份 [2024] 295.8亿美元
预测年份 [2030] 543.4亿美元
复合年增长率（%） 10.49%

市场动态：快速发展的融合蛋白市场，按产品类型、应用、最终用户和治疗领域揭示关键市场洞察

按产品类型、应用、最终用户和治疗领域划分，融合蛋白市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 在按产品类型、应用、最终用户和治疗领域使用融合蛋白的新型治疗方法越来越多地采用，用于慢性疾病的标靶治疗
    • 癌症和自体免疫疾病盛行率上升推动了对先进融合蛋白疗法的需求
    • 支持扩大药品製造能力和融合蛋白生产的创新技术
  • 市场限制因素
    • 按产品类型、应用、最终用户和治疗领域分類的融合蛋白开发和生产成本较高
  • 市场机会
    • 按产品类型、应用、最终用户和治疗领域扩展生物製药研究，并专注于多功能融合蛋白
    • 增加生技研发投资，依产品类型、应用、最终用户和治疗领域开发下一代融合蛋白
  • 市场挑战
    • 按产品类型、应用、最终用户和治疗领域对融合蛋白的生产和商业化提出严格的监管要求

波特五力：依产品类型、应用、最终用户和治疗领域开拓融合蛋白市场的策略工具

波特的五力框架是了解融合蛋白市场、按产品类型、应用、最终用户和治疗领域分類的竞争格局的关键工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更具弹性的市场地位。

PESTLE分析：了解融合蛋白市场、产品类型、应用、最终用户和治疗领域的外部影响

外部宏观环境因素在塑造融合蛋白市场、产品类型、应用、最终用户和治疗领域的性能动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解融合蛋白市场、产品类型、应用、最终用户和治疗领域的竞争格局

按融合蛋白市场、产品类型、应用、最终用户和治疗领域进行详细的市场占有率分析，可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位基质融合蛋白市场，按产品类型、应用、最终用户和治疗领域分類的供应商绩效评估

FPNV 定位矩阵是根据融合蛋白市场、产品类型、应用、最终用户和治疗领域评估供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议，按产品类型、应用、最终用户和治疗领域绘製融合蛋白市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，按产品类型、应用、最终用户和治疗领域对融合蛋白市场进行策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 按产品类型、应用、最终用户和治疗领域更多地采用利用融合蛋白的新治疗方法，用于慢性疾病的标靶治疗
      • 癌症和自体免疫疾病发生率的上升推动了对先进融合蛋白疗法的需求
      • 支持扩大药品製造能力和融合蛋白生产的创新技术
    • 抑制因素
      • 按产品类型、应用、最终用户和治疗领域分類的融合蛋白开发和生产成本较高
    • 机会
      • 扩大生物製药研究，重点关注融合蛋白产品类型、应用、最终用户和治疗领域的多功能性
      • 增加生技研发投资，依产品类型、应用、最终用户和治疗领域开发下一代融合蛋白
    • 任务
      • 按产品类型、应用、最终用户和治疗领域对融合蛋白的生产和商业化提出严格的监管要求
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章融合蛋白市场：依产品类型

  • 化学合成的融合蛋白
  • 重组融合蛋白

第七章融合蛋白市场：依应用

  • 诊断用途
    • 疾病诊断
  • 研究用途
    • 药物开发
    • 蛋白质体学研究
  • 治疗应用
    • 自体免疫疾病
    • 肿瘤学
      • 癌症免疫治疗
      • 标靶治疗
    • 罕见疾病

第 8 章 融合蛋白市场：按最终用户

  • 学术研究所
  • 生物製药公司
  • 合约研究组织

第九章融合蛋白市场：依治疗领域

  • 心血管疾病
  • 感染疾病
    • 细菌感染疾病
    • 病毒感染
  • 代谢紊乱
  • 肿瘤学
    • 造血系统恶性
    • 固态肿瘤

第10章美洲融合蛋白市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太融合蛋白市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲融合蛋白市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • 1. Abcam plc
  • 2. Abnova Corporation
  • 3. ACROBiosystems Inc.
  • 4. Agilent Technologies, Inc.
  • 5. Bio-Rad Laboratories, Inc.
  • 6. Cell Signaling Technology, Inc.
  • 7. Creative Diagnostics
  • 8. Enzo Life Sciences, Inc.
  • 9. GE Healthcare
  • 10. GenScript Biotech Corporation
  • 11. Merck KGaA
  • 12. OriGene Technologies, Inc.
  • 13. PeproTech, Inc.
  • 14. Promega Corporation
  • 15. ProSpec-Tany TechnoGene Ltd.
  • 16. R&D Systems, Inc.
  • 17. Rockland Immunochemicals, Inc.
  • 18. Santa Cruz Biotechnology, Inc.
  • 19. Sino Biological Inc.
  • 20. Thermo Fisher Scientific Inc.
Product Code: MRR-2B5802CFEB58

The Fusion Proteins Market was valued at USD 27.02 billion in 2023, expected to reach USD 29.58 billion in 2024, and is projected to grow at a CAGR of 10.49%, to USD 54.34 billion by 2030.

Fusion proteins, a revolutionary advancement in biotechnology, are engineered proteins formed by the genetic fusion of two distinct protein sequences, leading to the creation of a single polypeptide chain with multifaceted biological functions. This technology offers enhanced targeted delivery and therapeutic efficacy, making it indispensable in fields like oncology, autoimmune diseases, and enzyme replacement therapy. The application scope is broad, with uses in drug development and delivery systems, diagnostics, and even agriculture. End-users mainly include pharmaceutical and biotechnology companies, research institutions, and healthcare organizations. The fusion proteins market is poised for significant growth due to increasing demand for novel biologics, advancements in genetic engineering, and rising investments in the biotechnology sector. Key growth drivers involve escalating prevalence of chronic diseases, the necessity for cost-effective biopharmaceuticals, and technological advancements in protein engineering. There are burgeoning opportunities in the development of fusion proteins for immunotherapy and personalized medicine, driven by the need for targeted treatments. However, challenges persist, such as high R&D costs, stringent regulatory landscapes, and complex production processes that can hinder market growth. Ethical concerns and patent issues also pose limitations. To thrive, companies should focus on innovative technologies like CRISPR, AI-driven protein design, and advanced molecular techniques to enhance fusion protein specificity and stability. Collaborations and partnerships with academic and research institutions may also foster new discoveries and product developments. The market is dynamic, characterized by rapid technological advancements and competitive forces, urging companies to stay agile and adaptive. Innovating within synthetic biology and exploring new therapeutic areas that address unmet clinical needs can offer lucrative pathways for growth. Aspiring businesses should leverage these innovations and adopt strategies to streamline production and regulatory processes for optimal market penetration.

KEY MARKET STATISTICS
Base Year [2023] USD 27.02 billion
Estimated Year [2024] USD 29.58 billion
Forecast Year [2030] USD 54.34 billion
CAGR (%) 10.49%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Fusion Proteins Market

The Fusion Proteins Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing adoption of novel therapeutic approaches utilizing fusion proteins for targeted treatment of chronic diseases
    • Rising prevalence of cancer and autoimmune diseases driving demand for advanced fusion protein treatments
    • Expansion of pharmaceutical manufacturing capabilities and innovative technologies supporting fusion protein production
  • Market Restraints
    • High development and production costs of fusion proteins
  • Market Opportunities
    • Expansion of biopharmaceutical research focusing on multifunctional fusion proteins
    • Increasing investment in biotechnological R&D for the development of next-generation fusion proteins
  • Market Challenges
    • Stringent regulatory requirements on the production and commercialization of fusion proteins

Porter's Five Forces: A Strategic Tool for Navigating the Fusion Proteins Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Fusion Proteins Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Fusion Proteins Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Fusion Proteins Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Fusion Proteins Market

A detailed market share analysis in the Fusion Proteins Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Fusion Proteins Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Fusion Proteins Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Fusion Proteins Market

A strategic analysis of the Fusion Proteins Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Fusion Proteins Market, highlighting leading vendors and their innovative profiles. These include Abcam plc, Abnova Corporation, ACROBiosystems Inc., Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Cell Signaling Technology, Inc., Creative Diagnostics, Enzo Life Sciences, Inc., GE Healthcare, GenScript Biotech Corporation, Merck KGaA, OriGene Technologies, Inc., PeproTech, Inc., Promega Corporation, ProSpec-Tany TechnoGene Ltd., R&D Systems, Inc., Rockland Immunochemicals, Inc., Santa Cruz Biotechnology, Inc., Sino Biological Inc., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Fusion Proteins Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product Type, market is studied across Chemically Synthesized Fusion Proteins and Recombinant Fusion Proteins.
  • Based on Application, market is studied across Diagnostic Applications, Research Applications, and Therapeutic Applications. The Diagnostic Applications is further studied across Disease Diagnostics. The Research Applications is further studied across Drug Development and Proteomics Research. The Therapeutic Applications is further studied across Autoimmune Diseases, Oncology, and Rare Diseases. The Oncology is further studied across Cancer Immunotherapy and Targeted Therapy.
  • Based on End User, market is studied across Academic and Research Institutes, Biopharmaceutical Companies, and Contract Research Organizations.
  • Based on Therapeutic Area, market is studied across Cardiovascular Diseases, Infectious Diseases, Metabolic Disorders, and Oncology. The Infectious Diseases is further studied across Bacterial Infections and Viral Infections. The Oncology is further studied across Hematological Malignancies and Solid Tumors.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing adoption of novel therapeutic approaches utilizing fusion proteins for targeted treatment of chronic diseases
      • 5.1.1.2. Rising prevalence of cancer and autoimmune diseases driving demand for advanced fusion protein treatments
      • 5.1.1.3. Expansion of pharmaceutical manufacturing capabilities and innovative technologies supporting fusion protein production
    • 5.1.2. Restraints
      • 5.1.2.1. High development and production costs of fusion proteins
    • 5.1.3. Opportunities
      • 5.1.3.1. Expansion of biopharmaceutical research focusing on multifunctional fusion proteins
      • 5.1.3.2. Increasing investment in biotechnological R&D for the development of next-generation fusion proteins
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory requirements on the production and commercialization of fusion proteins
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Fusion Proteins Market, by Product Type

  • 6.1. Introduction
  • 6.2. Chemically Synthesized Fusion Proteins
  • 6.3. Recombinant Fusion Proteins

7. Fusion Proteins Market, by Application

  • 7.1. Introduction
  • 7.2. Diagnostic Applications
    • 7.2.1. Disease Diagnostics
  • 7.3. Research Applications
    • 7.3.1. Drug Development
    • 7.3.2. Proteomics Research
  • 7.4. Therapeutic Applications
    • 7.4.1. Autoimmune Diseases
    • 7.4.2. Oncology
      • 7.4.2.1. Cancer Immunotherapy
      • 7.4.2.2. Targeted Therapy
    • 7.4.3. Rare Diseases

8. Fusion Proteins Market, by End User

  • 8.1. Introduction
  • 8.2. Academic and Research Institutes
  • 8.3. Biopharmaceutical Companies
  • 8.4. Contract Research Organizations

9. Fusion Proteins Market, by Therapeutic Area

  • 9.1. Introduction
  • 9.2. Cardiovascular Diseases
  • 9.3. Infectious Diseases
    • 9.3.1. Bacterial Infections
    • 9.3.2. Viral Infections
  • 9.4. Metabolic Disorders
  • 9.5. Oncology
    • 9.5.1. Hematological Malignancies
    • 9.5.2. Solid Tumors

10. Americas Fusion Proteins Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Fusion Proteins Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Fusion Proteins Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abcam plc
  • 2. Abnova Corporation
  • 3. ACROBiosystems Inc.
  • 4. Agilent Technologies, Inc.
  • 5. Bio-Rad Laboratories, Inc.
  • 6. Cell Signaling Technology, Inc.
  • 7. Creative Diagnostics
  • 8. Enzo Life Sciences, Inc.
  • 9. GE Healthcare
  • 10. GenScript Biotech Corporation
  • 11. Merck KGaA
  • 12. OriGene Technologies, Inc.
  • 13. PeproTech, Inc.
  • 14. Promega Corporation
  • 15. ProSpec-Tany TechnoGene Ltd.
  • 16. R&D Systems, Inc.
  • 17. Rockland Immunochemicals, Inc.
  • 18. Santa Cruz Biotechnology, Inc.
  • 19. Sino Biological Inc.
  • 20. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. FUSION PROTEINS MARKET RESEARCH PROCESS
  • FIGURE 2. FUSION PROTEINS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL FUSION PROTEINS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL FUSION PROTEINS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL FUSION PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL FUSION PROTEINS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL FUSION PROTEINS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS FUSION PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS FUSION PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES FUSION PROTEINS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES FUSION PROTEINS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC FUSION PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC FUSION PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA FUSION PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA FUSION PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. FUSION PROTEINS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. FUSION PROTEINS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. FUSION PROTEINS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL FUSION PROTEINS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL FUSION PROTEINS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL FUSION PROTEINS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. FUSION PROTEINS MARKET DYNAMICS
  • TABLE 7. GLOBAL FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL FUSION PROTEINS MARKET SIZE, BY CHEMICALLY SYNTHESIZED FUSION PROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL FUSION PROTEINS MARKET SIZE, BY RECOMBINANT FUSION PROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL FUSION PROTEINS MARKET SIZE, BY DISEASE DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL FUSION PROTEINS MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL FUSION PROTEINS MARKET SIZE, BY PROTEOMICS RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL FUSION PROTEINS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL FUSION PROTEINS MARKET SIZE, BY CANCER IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL FUSION PROTEINS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL FUSION PROTEINS MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL FUSION PROTEINS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL FUSION PROTEINS MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL FUSION PROTEINS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL FUSION PROTEINS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL FUSION PROTEINS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL FUSION PROTEINS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL FUSION PROTEINS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL FUSION PROTEINS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL FUSION PROTEINS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS FUSION PROTEINS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 71. BRAZIL FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 76. CANADA FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. CANADA FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 80. CANADA FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 81. CANADA FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 82. MEXICO FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. MEXICO FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. MEXICO FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 85. MEXICO FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 86. MEXICO FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 87. MEXICO FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 88. MEXICO FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 89. MEXICO FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 90. MEXICO FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 91. MEXICO FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED STATES FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED STATES FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED STATES FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED STATES FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED STATES FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED STATES FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED STATES FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED STATES FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED STATES FUSION PROTEINS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC FUSION PROTEINS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 114. AUSTRALIA FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. AUSTRALIA FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. AUSTRALIA FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 117. AUSTRALIA FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 118. AUSTRALIA FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 119. AUSTRALIA FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 120. AUSTRALIA FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 121. AUSTRALIA FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 122. AUSTRALIA FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 123. AUSTRALIA FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 124. CHINA FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. CHINA FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. CHINA FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 127. CHINA FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 128. CHINA FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 129. CHINA FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 130. CHINA FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. CHINA FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 132. CHINA FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 133. CHINA FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 134. INDIA FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. INDIA FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. INDIA FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 137. INDIA FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 138. INDIA FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 139. INDIA FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 140. INDIA FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. INDIA FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 142. INDIA FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 143. INDIA FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 144. INDONESIA FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. INDONESIA FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. INDONESIA FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 147. INDONESIA FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 148. INDONESIA FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 149. INDONESIA FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 150. INDONESIA FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151. INDONESIA FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 152. INDONESIA FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 153. INDONESIA FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 154. JAPAN FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. JAPAN FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 156. JAPAN FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 157. JAPAN FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 158. JAPAN FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 159. JAPAN FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 160. JAPAN FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 161. JAPAN FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 162. JAPAN FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 163. JAPAN FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 164. MALAYSIA FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. MALAYSIA FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 166. MALAYSIA FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 167. MALAYSIA FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 168. MALAYSIA FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 169. MALAYSIA FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 170. MALAYSIA FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 171. MALAYSIA FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 172. MALAYSIA FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 173. MALAYSIA FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 174. PHILIPPINES FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. PHILIPPINES FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 176. PHILIPPINES FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 177. PHILIPPINES FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 178. PHILIPPINES FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 179. PHILIPPINES FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 180. PHILIPPINES FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 181. PHILIPPINES FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 182. PHILIPPINES FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 183. PHILIPPINES FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 184. SINGAPORE FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. SINGAPORE FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 186. SINGAPORE FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 187. SINGAPORE FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 188. SINGAPORE FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 189. SINGAPORE FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 190. SINGAPORE FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 191. SINGAPORE FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 192. SINGAPORE FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 193. SINGAPORE FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 194. SOUTH KOREA FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. SOUTH KOREA FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 196. SOUTH KOREA FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 197. SOUTH KOREA FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 198. SOUTH KOREA FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH KOREA FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH KOREA FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH KOREA FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH KOREA FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH KOREA FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 204. TAIWAN FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. TAIWAN FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 206. TAIWAN FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 207. TAIWAN FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 208. TAIWAN FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 209. TAIWAN FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 210. TAIWAN FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 211. TAIWAN FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 212. TAIWAN FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 213. TAIWAN FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 214. THAILAND FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. THAILAND FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 216. THAILAND FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 217. THAILAND FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 218. THAILAND FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 219. THAILAND FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 220. THAILAND FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 221. THAILAND FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 222. THAILAND FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 223. THAILAND FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 224. VIETNAM FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. VIETNAM FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 226. VIETNAM FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 227. VIETNAM FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 228. VIETNAM FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 229. VIETNAM FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 230. VIETNAM FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 231. VIETNAM FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 232. VIETNAM FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 233. VIETNAM FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA FUSION PROTEINS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 245. DENMARK FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 246. DENMARK FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 247. DENMARK FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 248. DENMARK FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 249. DENMARK FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 250. DENMARK FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 251. DENMARK FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 252. DENMARK FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 253. DENMARK FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 254. DENMARK FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 255. EGYPT FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. EGYPT FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 257. EGYPT FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 258. EGYPT FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 259. EGYPT FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 260. EGYPT FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 261. EGYPT FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 262. EGYPT FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 263. EGYPT FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 264. EGYPT FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 265. FINLAND FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. FINLAND FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 267. FINLAND FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 268. FINLAND FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 269. FINLAND FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 270. FINLAND FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 271. FINLAND FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 272. FINLAND FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 273. FINLAND FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 274. FINLAND FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 275. FRANCE FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 276. FRANCE FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 277. FRANCE FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 278. FRANCE FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 279. FRANCE FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 280. FRANCE FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 281. FRANCE FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 282. FRANCE FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 283. FRANCE FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 284. FRANCE FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 285. GERMANY FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 286. GERMANY FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 287. GERMANY FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 288. GERMANY FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 289. GERMANY FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 290. GERMANY FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 291. GERMANY FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 292. GERMANY FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 293. GERMANY FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 294. GERMANY FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 295. ISRAEL FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 296. ISRAEL FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 297. ISRAEL FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 298. ISRAEL FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 299. ISRAEL FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 300. ISRAEL FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 301. ISRAEL FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 302. ISRAEL FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 303. ISRAEL FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 304. ISRAEL FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 305. ITALY FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 306. ITALY FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 307. ITALY FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 308. ITALY FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 309. ITALY FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 310. ITALY FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 311. ITALY FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 312. ITALY FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 313. ITALY FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 314. ITALY FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 315. NETHERLANDS FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 316. NETHERLANDS FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 317. NETHERLANDS FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 318. NETHERLANDS FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 319. NETHERLANDS FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 320. NETHERLANDS FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 321. NETHERLANDS FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 322. NETHERLANDS FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 323. NETHERLANDS FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 324. NETHERLANDS FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 325. NIGERIA FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 326. NIGERIA FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 327. NIGERIA FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 328. NIGERIA FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 329. NIGERIA FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 330. NIGERIA FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 331. NIGERIA FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 332. NIGERIA FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 333. NIGERIA FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 334. NIGERIA FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 335. NORWAY FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 336. NORWAY FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 337. NORWAY FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 338. NORWAY FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 339. NORWAY FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 340. NORWAY FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 341. NORWAY FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 342. NORWAY FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 343. NORWAY FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 344. NORWAY FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 345. POLAND FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 346. POLAND FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 347. POLAND FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 348. POLAND FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 349. POLAND FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 350. POLAND FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 351. POLAND FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)